Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBT124 vs Avastin in First-line NSCLC
NCT02879097Phase 3Unknown
- Sponsor
- Cipla BioTec
- Start
- Dec 2016
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of bevacizumab biosimilar (CBT124) in non-small cell lung carcinoma (NSCLC), sponsored by Cipla BioTec. Status: unknown.
02
Drugs
bevacizumab biosimilar (CBT124)
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT02879097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02879097.